MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.570
0.000
0.00%
Closed 16:00 01/17 EST
OPEN
3.560
PREV CLOSE
3.570
HIGH
3.591
LOW
3.500
VOLUME
66.80K
TURNOVER
--
52 WEEK HIGH
4.180
52 WEEK LOW
1.900
MARKET CAP
109.78M
P/E (TTM)
-2.3512
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OTIC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OTIC News

  • Otonomy Provides Corporate and Product Pipeline Update
  • GlobeNewswire.01/09 12:30
  • Otonomy 8-K Includes Press Release With Corporate, Product Pipeline Update
  • Benzinga.01/09 12:29
  • Should You Worry About Otonomy, Inc.'s (NASDAQ:OTIC) CEO Salary Level?
  • Simply Wall St..01/07 17:31
  • The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger
  • Benzinga.01/03 12:55

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About OTIC

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
More

Webull offers Otonomy Inc (OTIC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.